To use all functions of this page, please activate cookies in your browser.
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Nilotinib
Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved as Tasigna® in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML)[1]. In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.[2] In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after 5 month of treatment. [3] Additional recommended knowledgeThe drug will carry a black box warning for possible heart complications. [4] References
Categories: Chemotherapeutic agents | Orphan drugs | Tyrosine kinase inhibitors |
||||||||||||||||||||||||||||||||||||||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nilotinib". A list of authors is available in Wikipedia. |
- High-Tech Material in a Salt Crust - Rresearchers simplify the production of MAX phases and high-performance materials
- Unconventional_superconductor
- Roald_Hoffmann
- New Measurement Method in Molecular Electronics - Method for measuring the conductivity of individual pharmaceutical and biological molecules
- Papaveretum